DENISE MILLER: Open Payments
NPI 1750380606 · HANOVER, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,721 in 90 payments from 25 companies in 2025. Trend: 2023 $1,836 · 2024 $2,011 · 2025 $1,721
Food & beverage: $1,721
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 13 | $221 |
| AstraZeneca Pharmaceuticals LP | 10 | $218 |
| ABBVIE INC. | 13 | $183 |
| Abbott Laboratories | 2 | $156 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $142 |
| Astellas Pharma US Inc | 3 | $87 |
| PFIZER INC. | 5 | $82 |
| Lilly USA, LLC | 5 | $81 |
| Esperion Therapeutics, Inc. | 4 | $74 |
| Mannkind Corporation | 2 | $69 |
Products named: INFINITY, Ozempic, FARXIGA, CAPLYTA, Veozah, ELIQUIS, NEXLETOL, QULIPTA.
Industry payments across PA — which companies pay providers there.
